Efficacy and Safety of Oral Dofetilide in Converting to and Maintaining Sinus Rhythm in Patients With Chronic Atrial Fibrillation or Atrial Flutter
Authors:
- 7 November 2000
- journal article
- other
- Published by Wolters Kluwer Health in Circulation
- Vol. 102 (19) , 2385-2390
Abstract
Background—This double-blind, multicenter, placebo-controlled study determined the efficacy and safety of dofetilide in converting atrial fibrillation (AF) or atrial flutter (AFl) to sinus rhythm (SR) and maintaining SR for 1 year.Methods and Results—Patients with AF or AFl (n=325) were randomized to 125, 250, or 500 μg dofetilide or placebo twice daily. Dosages were adjusted for QTc response and, after 105 patients were enrolled, for calculated creatinine clearance (ClCr). Pharmacological cardioversion rates for 125, 250, and 500 μg dofetilide were 6.1%, 9.8%, and 29.9%, respectively, versus 1.2% for placebo (250 and 500 μg versus placebo;P=0.015 andPP=0.001). Two cases of torsade de pointes occurred, 1 on day 2 and the other on day 3 (0.8% of all patients given active drug); 1 sudden cardiac death, classified as proarrhythmic, occurred on day 8 (0.4% of all patients given active drug).Conclusions—Dofetilide, a new class III antiarrhythmic agent, is moderately effective in cardioverting AF or AFl to SR and significantly effective in maintaining SR for 1 year. In-hospital initiation and dosage adjustment based on QTc and ClCrare necessary to minimize a small but nonnegligible proarrhythmic risk.Keywords
This publication has 11 references indexed in Scilit:
- Dofetilide in Patients with Congestive Heart Failure and Left Ventricular DysfunctionNew England Journal of Medicine, 1999
- Drug Treatment of Atrial Fibrillation in the Managed Care Era 11Supported in part by Grant RO1 HL38408 from the United States Public Health Service, National Institutes of Health, National Heart, Lung, and Blood Institute, Bethesda, Maryland.The American Journal of Cardiology, 1998
- Rhythm Management in Atrial Fibrillation—With a Primary Emphasis on Pharmacological Therapy: Part 1Pacing and Clinical Electrophysiology, 1998
- Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIATThe Lancet, 1997
- Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIATThe Lancet, 1997
- Pharmacokinetic and pharmacodynamic modeling of the effects of oral and intravenous administrations of dofetilide on ventricular repolarization*Clinical Pharmacology & Therapeutics, 1995
- Managing Chronic Atrial Fibrillation: A Markov Decision Analysis Comparing Warfarin, Quinidine, and Low-Dose AmiodaroneAnnals of Internal Medicine, 1994
- Pharmacodynamics and Pharmacokinetics of the Class III Antiarrhythmic Agent Dofetilide (UK-68,798) in HumansJournal of Cardiovascular Pharmacology, 1993
- Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillationJACC, 1992
- Clinical and electrophysiologic effects of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with angina pectorisThe American Journal of Cardiology, 1992